UY26696A1 - METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN - Google Patents
METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEINInfo
- Publication number
- UY26696A1 UY26696A1 UY26696A UY26696A UY26696A1 UY 26696 A1 UY26696 A1 UY 26696A1 UY 26696 A UY26696 A UY 26696A UY 26696 A UY26696 A UY 26696A UY 26696 A1 UY26696 A1 UY 26696A1
- Authority
- UY
- Uruguay
- Prior art keywords
- ryk
- anglogenesis
- proteins
- diseases
- protein
- Prior art date
Links
- 230000001105 regulatory effect Effects 0.000 title abstract 2
- 230000033115 angiogenesis Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se encontró que la proteína Ryk tenía una novedosa actividad en la regulación de la anglogénesis. Se construyeron nuevas proteínas Ryk variantes que son ventajosas para modular la actividad formadora de capilares de las células endoteliales. Las proteínas Ryk variantes pueden ser utilizadas como agentes terapéuticos en enfermedades tales como el cáncer, la cicatrización de heridas, las retinopatías diabéticas, la degeneración macular y las enfermedades cardiovasculares, así como otras enfermedades o trastornos clínicos en la que la anglogénesis está involucrada en la causa o el tratamiento de la enfermedad.The Ryk protein was found to have novel activity in regulating anglogenesis. New variant Ryk proteins were constructed that are advantageous for modulating capillary-forming activity of endothelial cells. Variant Ryk proteins can be used as therapeutic agents in diseases such as cancer, wound healing, diabetic retinopathy, macular degeneration, and cardiovascular disease, as well as other diseases or clinical disorders in which anglogenesis is involved in cause or treatment of the disease.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56878300A | 2000-05-10 | 2000-05-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY26696A1 true UY26696A1 (en) | 2001-12-28 |
Family
ID=24272718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY26696A UY26696A1 (en) | 2000-05-10 | 2001-05-08 | METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1287121A2 (en) |
| JP (1) | JP2004527206A (en) |
| AR (1) | AR028424A1 (en) |
| AU (1) | AU2001261343A1 (en) |
| CA (1) | CA2408349A1 (en) |
| CO (1) | CO5300464A1 (en) |
| DO (1) | DOP2001000164A (en) |
| EC (1) | ECSP014068A (en) |
| GT (1) | GT200100079A (en) |
| PE (1) | PE20011218A1 (en) |
| SV (1) | SV2002000442A (en) |
| UY (1) | UY26696A1 (en) |
| WO (1) | WO2001085789A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1471934A2 (en) * | 2002-02-06 | 2004-11-03 | DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung | Kinases involved in the regulation of energy homeostasis |
| JO3283B1 (en) | 2011-04-26 | 2018-09-16 | Sanofi Sa | Composition including Afflipersept, Folinic Acid, 5- Fluorouracil (5- Fu) and Irenosetan (FOLFIRI) |
| TR201909951T4 (en) | 2014-07-18 | 2019-07-22 | Sanofi Sa | A method for predicting the outcome of aflibercept treatment of a patient suspected of having cancer. |
| US20250027945A1 (en) * | 2021-08-18 | 2025-01-23 | The Regents Of The University Of California | Anti-related-to-receptor tyrosine kinase (ryk) antibodies and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107472A (en) * | 1992-05-11 | 2000-08-22 | Ludwig Institute For Cancer Research | Receptor-type tyrosine kinase-like molecules |
| CA2208319A1 (en) * | 1994-12-23 | 1996-07-04 | Ludwig Institute For Cancer Research | Assay, receptor proteins and ligands |
| WO1999064589A1 (en) * | 1998-06-11 | 1999-12-16 | Astrazeneca Ab | Human receptor tyrosine kinase |
| WO2000024415A2 (en) * | 1998-10-28 | 2000-05-04 | Cornell Research Foundation, Inc. | Methods for regulating angiogenesis and vascular integrity using trk receptor ligands |
-
2001
- 2001-05-07 GT GT200100079A patent/GT200100079A/en unknown
- 2001-05-07 AR ARP010102149A patent/AR028424A1/en not_active Application Discontinuation
- 2001-05-08 UY UY26696A patent/UY26696A1/en not_active Application Discontinuation
- 2001-05-09 WO PCT/US2001/015043 patent/WO2001085789A2/en not_active Ceased
- 2001-05-09 CA CA002408349A patent/CA2408349A1/en not_active Abandoned
- 2001-05-09 CO CO01036462A patent/CO5300464A1/en unknown
- 2001-05-09 SV SV2001000442A patent/SV2002000442A/en not_active Application Discontinuation
- 2001-05-09 JP JP2001582388A patent/JP2004527206A/en active Pending
- 2001-05-09 AU AU2001261343A patent/AU2001261343A1/en not_active Abandoned
- 2001-05-09 EC EC2001004068A patent/ECSP014068A/en unknown
- 2001-05-09 EP EP01935233A patent/EP1287121A2/en not_active Withdrawn
- 2001-05-10 PE PE2001000417A patent/PE20011218A1/en not_active Application Discontinuation
- 2001-05-10 DO DO2001000164A patent/DOP2001000164A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO5300464A1 (en) | 2003-07-31 |
| AR028424A1 (en) | 2003-05-07 |
| AU2001261343A1 (en) | 2001-11-20 |
| EP1287121A2 (en) | 2003-03-05 |
| PE20011218A1 (en) | 2002-02-01 |
| DOP2001000164A (en) | 2002-05-15 |
| WO2001085789A2 (en) | 2001-11-15 |
| ECSP014068A (en) | 2002-02-25 |
| GT200100079A (en) | 2001-12-31 |
| SV2002000442A (en) | 2002-07-03 |
| WO2001085789A3 (en) | 2002-05-16 |
| JP2004527206A (en) | 2004-09-09 |
| CA2408349A1 (en) | 2001-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28396A1 (en) | VEGF TRUMPS AND THERAPEUTIC USES OF THE SAME | |
| TR200101307T2 (en) | Antranilic acid amides and their use as drugs. | |
| CY1107248T1 (en) | SUSPENED PROTEINS | |
| ECSP034548A (en) | DERIVATIVES OF QUINOLINONA AS INHIBITORS OF TIROSIN QUINASA | |
| CU23208A3 (en) | OXAZOLIDINONAS REPLACED AND ITS USE IN THE FIELD OF THE SANGUINEA COAGULATION | |
| EA200400482A1 (en) | KERATINOCYCES SUITABLE FOR APPLICATION AS A BIOLOGICALLY ACTIVE SUBSTANCE IN THE TREATMENT OF THE RAS | |
| AR039511A1 (en) | AGENTS THAT REGULATE, INHIBIT, OR MODULATE THE ACTIVITY AND / OR EXPRESSION OF THE GROWTH FACTOR OF THE CONJUNCTIVE FABRIC (CTGF) AS A SINGLE MEDIUM TO DECREASE INTRAOCULAR PRESSURE AND TO TREAT GLAUCOMATOUS / NEUROPATHY RETINOPATHY | |
| ES2080837T3 (en) | TREATMENT OF STATES AND DISEASES. | |
| ATE478670T1 (en) | RECEPTOR-SELECTIVE CANNABIMIMETICS AMINOALKYLINDOLS | |
| SV1995000007A (en) | DERIVATIVES OF 5-SUBSTITUTED MYCOPHENOLIC ACID. | |
| Philp et al. | Thymosin beta 4 induces hair growth via stem cell migration and differentiation | |
| NO20065027L (en) | Process for Preparation of a Biologically Active, Recombinant Human Human Coagulation Factor VIII in a Cell Culture Medium Allowing Expression and Secretion of the Polypeptide | |
| Gileva et al. | Hirudotherapy | |
| Tak et al. | Oral submucous fibrosis: A review article on etiopathogenesis | |
| UY26696A1 (en) | METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN | |
| DK1343472T3 (en) | Thixotropic nasal spray | |
| ES2162331T3 (en) | USE OF THE NERVOUS TISSUE GROWTH FACTOR FOR CONSERVATION, CROP OR TREATMENT OF THE CORNEA. | |
| AR030345A1 (en) | METHOD OF TREATMENT OF DISORDERS RELATED TO ANGIOGENESIS | |
| ATE556134T1 (en) | MESENCHYMA STEM CELLS AND USES THEREOF | |
| Chelmu Voda et al. | Update on the Study of Angiogenesis in Surgical Wounds in Patients with Childhood Obesity. | |
| ATE390937T1 (en) | METHODS OF TREATING HYPERPROLIFERATIVE DISEASES USING HUMAN MDA-7 | |
| Matthews-Brzozowska et al. | Revitalization of facial skin based on preparations of patient own blood | |
| DE60107444D1 (en) | USE OF A POLLEN EXTRACT CONTAINER FOR THE TREATMENT OF EDEMS | |
| UY26649A1 (en) | PROTEIN THAT HAS ANGIOGENESIS MODULATING ACTIVITY | |
| ATE374048T1 (en) | USE OF MATRIX PROTEIN FOR CONTROLLED TISSUE REGENERATIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20131119 |